Novel therapeutic approaches based on the targeting of microenvironment-derived survival pathways in human cancer: experimental models and translational issues.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Current pharmaceutical design

• Publication date

  2007-01-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/138161207780162872PMID 17348845
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cell migration in tumors.

  2005cited by this paper
• A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma.

  2005cited by this paper
• Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.

  2005cited by this paper
• The role of B-RAF in melanoma

  2005cited by this paper
• Combination Therapy with Interleukin-6 Receptor Superantagonist Sant7 and Dexamethasone Induces Antitumor Effects in a Novel SCID-hu In vivo Model of Human Multiple Myeloma

  2005cited by this paper
• A SCID-hu in vivo model of human Waldenström macroglobulinemia.

  2005cited by this paper
• Nanovector therapeutics.

  2005cited by this paper
• Mechanisms of cancer metastasis to the bone

  2005cited by this paper
• Antitumor therapeutic strategies based on the targeting of epidermal growth factor-induced survival pathways.

  2005cited by this paper
• The role of focal-adhesion kinase in cancer — a new therapeutic opportunity

  2005cited by this paper
• New targeted approaches in chronic myeloid leukemia.

  2005cited by this paper
• Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.

  2005cited by this paper
• Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype.

  2005cited by this paper
• Clinical Proteomics: From Biomarker Discovery and Cell Signaling Profiles to Individualized Personal Therapy

  2005cited by this paper
• Integrin function and signaling as pharmacological targets in cardiovascular diseases and in cancer.

  2005cited by this paper
• Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid

  2005cited by this paper
• Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function.

  2005cited by this paper
• IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy.

  2005cited by this paper
• Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.

  2005cited by this paper
• Second nature: Biological functions of the Raf‐1 “kinase”

  2005cited by this paper
• The p53 pathway: positive and negative feedback loops

  2005cited by this paper
• The urokinase receptor as a potential target in cancer therapy.

  2004cited by this paper
• Dynamic process of prostate cancer metastasis to bone

  2004cited by this paper
• Targeting the mitogen-activated protein kinase cascade to treat cancer

  2004cited by this paper
• Targeting angiogenesis in cancer: clinical development of bevacizumab

  2004cited by this paper
• Genome wide analysis of TNF-inducible genes reveals that antioxidant enzymes are induced by TNF and responsible for elimination of ROS.

  2004cited by this paper
• Targeting Multiple Myeloma Cells and Their Bone Marrow Microenvironment

  2004cited by this paper
• Integrin signalling during tumour progression

  2004cited by this paper
• Critical Role of Endogenous Akt/IAPs and MEK1/ERK Pathways in Counteracting Endoplasmic Reticulum Stress-induced Cell Death*

  2004cited by this paper
• A clinically relevant SCID-hu in vivo model of human multiple myeloma.

  2004cited by this paper
• Maximizing clinical benefit with trastuzumab.

  2004cited by this paper
• Advances in biology of multiple myeloma: clinical applications.

  2004cited by this paper
• Eph receptor tyrosine kinases in tumor and tumor microenvironment.

  2004cited by this paper
• Vascular endothelial growth factor: basic science and clinical progress.

  2004cited by this paper
• To be, or not to be: NF-kappaB is the answer--role of Rel/NF-kappaB in the regulation of apoptosis.

  2003cited by this paper
• Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis.

  2003cited by this paper
• Mouse cancer models as a platform for performing preclinical therapeutic trials.

  2003cited by this paper
• The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited

  2003cited by this paper
• Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death

  2003cited by this paper
• Aetiology of bone disease and the role of bisphosphonates in multiple myeloma.

  2003cited by this paper
• The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.

  2003cited by this paper
• Extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK)-independent functions of Raf kinases.

  2002cited by this paper
• Molecular mechanisms of novel therapeutic approaches for multiple myeloma

  2002cited by this paper
• Addiction to Oncogenes--the Achilles Heal of Cancer

  2002cited by this paper
• RANK‐Fc in myeloma

  2002cited by this paper
• RANK (receptor activator of nuclear factor‐κB) and RANKL expression in multiple myeloma

  2002cited by this paper
• NF-kappa B as a therapeutic target in multiple myeloma.

  2002cited by this paper
• Chronic B cell malignancies and bone marrow microenvironment.

  2002cited by this paper
• The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells.

  2002cited by this paper
• The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro

  2001cited by this paper
• The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

  2001cited by this paper
• The microenvironment of the tumour–host interface

  2001cited by this paper
• Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy.

  2001cited by this paper
• Independent control of cell survival by Raf-1 and Bcl-2 at the mitochondria

  2001cited by this paper
• Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma

  2001cited by this paper
• Angiogenesis in multiple myeloma.

  2001cited by this paper
• Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.

  2001cited by this paper
• Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK–ERK independent mechanism

  2001cited by this paper
• Forkhead transcription factors are targets of signalling by the proto‐oncogene PKB (C‐AKT)

  2000cited by this paper
• Cooperative Signaling between α6β4Integrin and ErbB-2 Receptor Is Required to Promote Phosphatidylinositol 3-Kinase-dependent Invasion*

  2000cited by this paper
• JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen‐activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells

  2000cited by this paper
• The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance

  2000cited by this paper
• Synergistic induction of growth arrest and apoptosis of human myeloma cells by the IL-6 super-antagonist Sant7 and Dexamethasone

  2000cited by this paper
• The influence of the microenvironment on the malignant phenotype.

  2000cited by this paper
• Redox regulation of cellular signalling.

  1999cited by this paper
• Critical determinants of cancer metastasis: rationale for therapy

  1999cited by this paper
• Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.

  1999cited by this paper
• Modeling human lung cancer in mice: similarities and shortcomings

  1999cited by this paper
• The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone.

  1998cited by this paper
• Recent insights into the role of integrins in cancer metastasis

  1998cited by this paper
• Interleukin-6-induced inhibition of multiple myeloma cell apoptosis: support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway.

  1998cited by this paper
• Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

  1998cited by this paper
• Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations.

  1998cited by this paper
• IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade.

  1997cited by this paper
• The development of a model for the homing of multiple myeloma cells to human bone marrow.

  1997cited by this paper
• The multiple roles of tumour stroma

  1997cited by this paper
• Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism

  1997cited by this paper
• Mechanisms of bone metastasis

  1997cited by this paper
• A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function

  1997cited by this paper
• Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery.

  1997cited by this paper
• Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death.

  1996cited by this paper
• Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells.

  1996cited by this paper
• Cytokine, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma.

  1995cited by this paper
• Interleukin-6 in human multiple myeloma.

  1995cited by this paper
• Expression of alpha 3 beta 1 integrin receptor and its ligands in human lung tumors.

  1995cited by this paper
• Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma.

  1995cited by this paper
• Generation of interleukin‐6 receptor antagonists by molecular‐modeling guided mutagenesis of residues important for gp130 activation.

  1994cited by this paper
• Interleukin-6 prevents dexamethasone-induced myeloma cell death.

  1994cited by this paper
• Tyrosine phosphorylation of JAK-TYK kinases in malignant plasma cell lines growth-stimulated by interleukins 6 and 11.

  1994cited by this paper
• Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion.

  1993cited by this paper
• Implantation and maintenance of functional human bone marrow in SCID-hu mice.

  1992cited by this paper
• Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption

  1992cited by this paper
• Long-term human hematopoiesis in the SCID-hu mouse

  1990cited by this paper
• The distribution of secondary growths in cancer of the breast. 1889.

  1989cited by this paper
• Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.

  1989cited by this paper
• Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease.

  1989cited by this paper
• The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function.

  1988cited by this paper
• Establishment of a human B-cell tumor in athymic mice.

  1987cited by this paper
• Enhanced success rate of transplantation with human tumors in cyclophosphamide-treated nude mice.

  1986cited by this paper
• Endocrine sensitivity of the receptor‐positive T61 human breast carcinoma serially grown in nude mice

  1985cited by this paper

• Oncogenic role of microRNA-20a in human multiple myeloma

  2017cites this paper
• MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment

  2016cites this paper
• MiRNome expression is deregulated in the peripheral lymphoid compartment of multiple myeloma

  2014cites this paper
• TRAP1 role in endoplasmic reticulum stress protection favors resistance to anthracyclins in breast carcinoma cells.

  2014cites this paper
• Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma

  2013cites this paper
• TRAP 1 role in endoplasmic reticulum stress protection favors resistance to anthracyclins in breast carcinoma cells

  2013cites this paper
• In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma

  2013cites this paper
• The PERK-eIF2α phosphorylation arm is a pro-survival pathway of BCR-ABL signaling and confers resistance to imatinib treatment in chronic myeloid leukemia cells

  2012cites this paper
• Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma

  2012cites this paper
• A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells

  2011cites this paper
• Proteomic analysis of neuroblastoma microenvironment: effect of the host-tumor interaction on disease progression.

  2009cites this paper
• Divergent Effects of Castration on Prostate Cancer in TRAMP Mice: Possible Implications for Therapy

  2008cites this paper
• Tumoricidal activity of endothelium-derived NO and the survival of metastatic cells with high GSH and Bcl-2 levels.

  2008cites this paper
• An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies.

  2008cites this paper
• Psychrophilic superoxide dismutase from Pseudoalteromonas haloplanktis: biochemical characterization and identification of a highly reactive cysteine residue.

  2006cites this paper